A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs LOXO 195 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Loxo Oncology
- 27 Feb 2018 Planned number of patients changed from 120 to 93.
- 03 Jun 2017 According to a Loxo Oncology media release, clinical proof-of-concept data from the first two patients treated has been published online.
- 03 Jun 2017 Status changed from planning to recruiting, according to a Loxo Oncology media release.